Role of medial prefrontal and orbitofrontal monoamine transporters and receptors in performance in an adjusting delay discounting procedure

Justin R. Yates, Jennifer L. Perry, Andrew C. Meyer, Cassandra Gipson-Reichardt, Richard Charnigo, Michael T. Bardo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Performance in an adjusting delay discounting procedure is predictive of drug abuse vulnerability; however, the shared underlying specific prefrontal neural systems linking delay discounting and increased addiction-like behaviors are unclear. Rats received direct infusions of methylphenidate (MPH; 6.25, 25.0, or 100 μg), amphetamine (AMPH; 0.25, 1.0, or 4.0 μg), or atomoxetine (ATO; 1.0, 4.0, or 16.0 μg) into either medial prefrontal cortex (mPFC) or orbitofrontal cortex (OFC) immediately prior to performance in an adjusting delay task. These drugs were examined because they are efficacious in treating impulse control disorders. Because dopamine (DA) and serotonin (5-HT) receptors are implicated in impulsive behavior, separate groups of rats received microinfusions of the DA receptor-selective drugs SKF 81297 (0.1 or 0.4 mg), SCH 23390 (0.25 or 1.0 mg), quinpirole (1.25 or 5.0 mg), and eticlopride (0.25 or 1.0 mg), or received microinfusions of the 5-HT receptor-selective drugs 8-OH-DPAT (0.025 or 0.1 μg), WAY 100635 (0.01 or 0.04 μg), DOI (2.5 or 10.0 μg), and ketanserin (0.1 or 0.4 μg). Impulsive choice was not altered significantly by MPH, AMPH, or ATO into either mPFC or OFC, indicating that neither of these prefrontal regions alone may mediate the systemic effect of ADHD medications on impulsive choice. However, quinpriole (1.25 μg) and eticlopride infused into mPFC increased impulsive choice, whereas 8-OH-DPAT infused into OFC decreased impulsive choice. These latter results demonstrate that blockade of DA D2 receptors in mPFC or activation of 5-HT1Areceptors in OFC increases impulsive choice in the adjusting delay procedure.

Original languageEnglish (US)
Pages (from-to)26-36
Number of pages11
JournalBrain Research
Volume1574
Issue number1
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Prefrontal Cortex
eticlopride
8-Hydroxy-2-(di-n-propylamino)tetralin
Serotonin Receptors
Disruptive, Impulse Control, and Conduct Disorders
Pharmaceutical Preparations
Quinpirole
Ketanserin
Methylphenidate
Dopamine D2 Receptors
Delay Discounting
Impulsive Behavior
Dopamine Receptors
Amphetamine
Substance-Related Disorders
Dopamine

Keywords

  • Adjusting delay discounting
  • Dopamine receptor
  • Dopamine transporter
  • Norepinephrine transporter
  • Rat
  • Serotonin receptor

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology
  • Medicine(all)

Cite this

Role of medial prefrontal and orbitofrontal monoamine transporters and receptors in performance in an adjusting delay discounting procedure. / Yates, Justin R.; Perry, Jennifer L.; Meyer, Andrew C.; Gipson-Reichardt, Cassandra; Charnigo, Richard; Bardo, Michael T.

In: Brain Research, Vol. 1574, No. 1, 2014, p. 26-36.

Research output: Contribution to journalArticle

Yates, Justin R. ; Perry, Jennifer L. ; Meyer, Andrew C. ; Gipson-Reichardt, Cassandra ; Charnigo, Richard ; Bardo, Michael T. / Role of medial prefrontal and orbitofrontal monoamine transporters and receptors in performance in an adjusting delay discounting procedure. In: Brain Research. 2014 ; Vol. 1574, No. 1. pp. 26-36.
@article{bbf4a5c3a3b44365aace697dc291fc65,
title = "Role of medial prefrontal and orbitofrontal monoamine transporters and receptors in performance in an adjusting delay discounting procedure",
abstract = "Performance in an adjusting delay discounting procedure is predictive of drug abuse vulnerability; however, the shared underlying specific prefrontal neural systems linking delay discounting and increased addiction-like behaviors are unclear. Rats received direct infusions of methylphenidate (MPH; 6.25, 25.0, or 100 μg), amphetamine (AMPH; 0.25, 1.0, or 4.0 μg), or atomoxetine (ATO; 1.0, 4.0, or 16.0 μg) into either medial prefrontal cortex (mPFC) or orbitofrontal cortex (OFC) immediately prior to performance in an adjusting delay task. These drugs were examined because they are efficacious in treating impulse control disorders. Because dopamine (DA) and serotonin (5-HT) receptors are implicated in impulsive behavior, separate groups of rats received microinfusions of the DA receptor-selective drugs SKF 81297 (0.1 or 0.4 mg), SCH 23390 (0.25 or 1.0 mg), quinpirole (1.25 or 5.0 mg), and eticlopride (0.25 or 1.0 mg), or received microinfusions of the 5-HT receptor-selective drugs 8-OH-DPAT (0.025 or 0.1 μg), WAY 100635 (0.01 or 0.04 μg), DOI (2.5 or 10.0 μg), and ketanserin (0.1 or 0.4 μg). Impulsive choice was not altered significantly by MPH, AMPH, or ATO into either mPFC or OFC, indicating that neither of these prefrontal regions alone may mediate the systemic effect of ADHD medications on impulsive choice. However, quinpriole (1.25 μg) and eticlopride infused into mPFC increased impulsive choice, whereas 8-OH-DPAT infused into OFC decreased impulsive choice. These latter results demonstrate that blockade of DA D2 receptors in mPFC or activation of 5-HT1Areceptors in OFC increases impulsive choice in the adjusting delay procedure.",
keywords = "Adjusting delay discounting, Dopamine receptor, Dopamine transporter, Norepinephrine transporter, Rat, Serotonin receptor",
author = "Yates, {Justin R.} and Perry, {Jennifer L.} and Meyer, {Andrew C.} and Cassandra Gipson-Reichardt and Richard Charnigo and Bardo, {Michael T.}",
year = "2014",
doi = "10.1016/j.brainres.2014.06.004",
language = "English (US)",
volume = "1574",
pages = "26--36",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Role of medial prefrontal and orbitofrontal monoamine transporters and receptors in performance in an adjusting delay discounting procedure

AU - Yates, Justin R.

AU - Perry, Jennifer L.

AU - Meyer, Andrew C.

AU - Gipson-Reichardt, Cassandra

AU - Charnigo, Richard

AU - Bardo, Michael T.

PY - 2014

Y1 - 2014

N2 - Performance in an adjusting delay discounting procedure is predictive of drug abuse vulnerability; however, the shared underlying specific prefrontal neural systems linking delay discounting and increased addiction-like behaviors are unclear. Rats received direct infusions of methylphenidate (MPH; 6.25, 25.0, or 100 μg), amphetamine (AMPH; 0.25, 1.0, or 4.0 μg), or atomoxetine (ATO; 1.0, 4.0, or 16.0 μg) into either medial prefrontal cortex (mPFC) or orbitofrontal cortex (OFC) immediately prior to performance in an adjusting delay task. These drugs were examined because they are efficacious in treating impulse control disorders. Because dopamine (DA) and serotonin (5-HT) receptors are implicated in impulsive behavior, separate groups of rats received microinfusions of the DA receptor-selective drugs SKF 81297 (0.1 or 0.4 mg), SCH 23390 (0.25 or 1.0 mg), quinpirole (1.25 or 5.0 mg), and eticlopride (0.25 or 1.0 mg), or received microinfusions of the 5-HT receptor-selective drugs 8-OH-DPAT (0.025 or 0.1 μg), WAY 100635 (0.01 or 0.04 μg), DOI (2.5 or 10.0 μg), and ketanserin (0.1 or 0.4 μg). Impulsive choice was not altered significantly by MPH, AMPH, or ATO into either mPFC or OFC, indicating that neither of these prefrontal regions alone may mediate the systemic effect of ADHD medications on impulsive choice. However, quinpriole (1.25 μg) and eticlopride infused into mPFC increased impulsive choice, whereas 8-OH-DPAT infused into OFC decreased impulsive choice. These latter results demonstrate that blockade of DA D2 receptors in mPFC or activation of 5-HT1Areceptors in OFC increases impulsive choice in the adjusting delay procedure.

AB - Performance in an adjusting delay discounting procedure is predictive of drug abuse vulnerability; however, the shared underlying specific prefrontal neural systems linking delay discounting and increased addiction-like behaviors are unclear. Rats received direct infusions of methylphenidate (MPH; 6.25, 25.0, or 100 μg), amphetamine (AMPH; 0.25, 1.0, or 4.0 μg), or atomoxetine (ATO; 1.0, 4.0, or 16.0 μg) into either medial prefrontal cortex (mPFC) or orbitofrontal cortex (OFC) immediately prior to performance in an adjusting delay task. These drugs were examined because they are efficacious in treating impulse control disorders. Because dopamine (DA) and serotonin (5-HT) receptors are implicated in impulsive behavior, separate groups of rats received microinfusions of the DA receptor-selective drugs SKF 81297 (0.1 or 0.4 mg), SCH 23390 (0.25 or 1.0 mg), quinpirole (1.25 or 5.0 mg), and eticlopride (0.25 or 1.0 mg), or received microinfusions of the 5-HT receptor-selective drugs 8-OH-DPAT (0.025 or 0.1 μg), WAY 100635 (0.01 or 0.04 μg), DOI (2.5 or 10.0 μg), and ketanserin (0.1 or 0.4 μg). Impulsive choice was not altered significantly by MPH, AMPH, or ATO into either mPFC or OFC, indicating that neither of these prefrontal regions alone may mediate the systemic effect of ADHD medications on impulsive choice. However, quinpriole (1.25 μg) and eticlopride infused into mPFC increased impulsive choice, whereas 8-OH-DPAT infused into OFC decreased impulsive choice. These latter results demonstrate that blockade of DA D2 receptors in mPFC or activation of 5-HT1Areceptors in OFC increases impulsive choice in the adjusting delay procedure.

KW - Adjusting delay discounting

KW - Dopamine receptor

KW - Dopamine transporter

KW - Norepinephrine transporter

KW - Rat

KW - Serotonin receptor

UR - http://www.scopus.com/inward/record.url?scp=84925359856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925359856&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2014.06.004

DO - 10.1016/j.brainres.2014.06.004

M3 - Article

VL - 1574

SP - 26

EP - 36

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1

ER -